ArticleObesity surgery2025
Effect of sugammadex on the prevention of postoperative lung atelectasis in patients undergoing metabolic and bariatric surgery: a retrospective study.
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Elevated preoperative red cell distribution width and incident infection after metabolic and bariatric surgery: a cohort study.Frontiers in nutrition · 2026Article
- Sugammadex and Postoperative Respiratory Failure in Head and Neck Surgery: A Cohort Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary atelectasis is a significant complication of metabolic and bariatric surgery (MBS). Sugammadex enables rapid neuromuscular blockade reversal compared to neostigmine, but its impact on atelectasis prevention remains unclear.
methodsThis retrospective multicenter study used the TriNetX database to analyze adult patients who underwent MBS between 2010 and 2024. Patients receiving rocuronium were divided into sugammadex and control (i.e., neostigmine use) groups. After propensity score matching, the outcomes were assessed at the 30-day follow-up. The primary outcome was the risk of pulmonary atelectasis, while secondary outcomes included pneumonia, respiratory failure, deep vein thrombosis (DVT), and intensive care unit (ICU) admission.
resultsAmong 19,606 propensity-matched pairs, sugammadex significantly reduced the risk of pulmonary atelectasis (0.83% vs. 1.33%, odds ratio [OR]: 0.62, 95% confidence interval [CI]: 0.51-0.76, p<0.001). The secondary outcomes showed no significant differences in pneumonia (0.36% vs. 0.45%, p=0.177), respiratory failure (0.36% vs. 0.40%, p=0.460), DVT (0.19% vs. 0.17%, p=0.722), or ICU admission (0.67% vs. 0.81%, p=0.111). Subgroup analyses demonstrated consistent protective effects of sugammadex against pulmonary atelectasis across different patient populations (with or without sleep apnea) and institutional settings (academic vs. non-academic centers). Female patients receiving sugammadex experienced significant reductions in both pulmonary atelectasis (OR: 0.59, p<0.001) and respiratory failure (OR: 0.64, p=0.028), whereas the benefit in male patients was not statistically significant.
conclusionSugammadex use was associated with a 38% reduction in postoperative pulmonary atelectasis compared to neostigmine use, suggesting that it may be a beneficial strategy for improving respiratory outcomes in patients undergoing MBS.
Indexed as
Identifiers
40614004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.